Physician profile
Dan Jacobs
NPI 1831213263
$11,578.85
in general payments reported to CMS, 2019-2025
26 companies · $1,911 in 2025
The $1,911 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,533 · 2020: $1,520 · 2021: $1,932 · 2022: $1,504 · 2023: $1,469 · 2024: $1,710 · 2025: $1,911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,090.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,090.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,924.45 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,505.93 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,201.63 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $1,155.47 | 2019-2025 | Rexulti |
| Allergan, INC. | $834.37 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $830.02 | 2019-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $765.42 | 2019-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $712.61 | 2020-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $693.85 | 2019-2022 | |
| Alkermes, INC. | $475.20 | 2021-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $350.11 | 2019-2024 | Invega Sustenna, Spravato |
| Teva Pharmaceuticals USA, INC. | $305.35 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Axsome Therapeutics, INC. | $153.90 | 2022-2025 | Auvelity |
| Eisai INC. | $128.60 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $125.30 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $118.98 | 2022-2023 | Quviviq |
| Harmony Biosciences LLC | $55.66 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $46.79 | 2025 | Cobenfy |
| Shire North American Group INC | $45.09 | 2019 | |
| Almatica Pharma LLC | $41.58 | 2022-2024 | Loreev Xr |
| Pacira Pharmaceuticals Incorporated | $26.36 | 2025 | Exparel |
| Corium, LLC | $22.88 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.99 | 2025 | |
| Bausch Health US, LLC | $16.43 | 2020 | |
| Noven Therapeutics, LLC | $12.59 | 2020 | |
| Merck Sharp & Dohme LLC | $12.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.